PET-CT Predicting Segement Specific Lymph Nodes Metastasis

Launched by FUDAN UNIVERSITY · Jul 23, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how well a special imaging test called PET-CT can predict whether lymph nodes are affected by cancer in patients with a type of lung cancer called non-small cell lung cancer (NSCLC). The researchers want to see if certain details from the PET-CT scan, like how much the cancer cells take up a specific type of sugar used in the scan and the size of the lymph nodes, can help identify if cancer has spread to specific lymph nodes before surgery. Participants will undergo surgery to remove lymph nodes, and the findings will help determine how accurate the PET-CT results were.

To be eligible for this trial, patients should have a single tumor or only some small nodules in the lungs, with the main tumor being 5 centimeters or smaller. They must not have any enlarged lymph nodes seen on previous scans, and they should not have received any prior cancer treatments. During the study, participants can expect to have their PET-CT results evaluated and then undergo surgery where their lymph nodes will be removed and examined. This study is currently looking for participants, and it is open to individuals of any gender between the ages of 18 and 80.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Solitary tumor, or multiple tumors with only ground-glass nodules (GGNs) apart from the primary lesion.
• • Diameter of the primary lesion ≤5cm, with a CTR between 0.5 and 1.
• • No enlarged mediastinal lymph nodes observed on preoperative contrast-enhanced CT.
• • Pathological confirmation of non-small cell lung cancer (NSCLC) either before or during surgery.
• • Systematic lymph node dissection performed during surgery.
• • No prior radiotherapy or chemotherapy for initial treatment.
• • No history of malignant tumors.
• Exclusion Criteria:
• • Locally advanced or distant metastasis.
• • Pleural dissemination observed during surgery.
• • History of malignant tumors.
• • Received neoadjuvant therapy.
• • Systematic lymph node dissection not performed during surgery.
• • Histopathological examination reveals lung malignancies other than non-small cell lung cancer (NSCLC).